CPRX · Investment summary · as of 29 July 2026
Priced close to what the business has demonstrated
Business type: mature and structurally stable
The operating path required by the price could not be established.
At $31.49, CPRX requires a 10% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 28%.
The value rests on an exit multiple of 11.3x and a terminal operating margin of 48%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Logged and scored; it rejects nothing.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Profitable (TTM operating margin 44.8%, Q1-2026 49.0%); operating margin above 40% for three consecutive fiscal years. |
| What do we forecast? | Revenue growth of 28% demonstrated; a terminal operating margin of 48%; an exit multiple of 11.3x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +18.2 percentage points. |
| What is it worth? | Twelve-month target $31.50, +0% from the struck price. Scenario-weighted expected return net of costs +0.0%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
Date not announced — no dated event that would resolve the disagreement is on file
Logged and scored; it rejects nothing. Realistic permanent-loss scenario, and its cause. Underwritten as at the last quarter for which the business was a going public concern, i.e. ignoring the merger: > Named cause: failure of the acquisition engine, with FIRDAPSE as the only load-bearing asset. > > Catalyst has no discovery capability (R&D = 2.2% of revenue) and every product is licensed or acquired. Its > growth is a function of doing deals. In 2025 it reviewed over 100 targets and did none. FYCOMPA demonstrated > that its deal underwriting can be wrong: ~$198m paid in Janua
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $31.50 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | Logged and scored; it rejects nothing. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +18.2 percentage points more growth than the price requires. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $27.71, which forces an immediate review.